CAPONNETTO, SALVATORE
 Distribuzione geografica
Continente #
NA - Nord America 1.332
EU - Europa 765
AS - Asia 206
AF - Africa 33
SA - Sud America 10
OC - Oceania 6
Totale 2.352
Nazione #
US - Stati Uniti d'America 1.310
IT - Italia 470
SE - Svezia 125
IN - India 63
SG - Singapore 56
CN - Cina 45
FI - Finlandia 37
EG - Egitto 30
DE - Germania 29
GB - Regno Unito 21
CA - Canada 19
FR - Francia 16
KR - Corea 15
UA - Ucraina 14
BG - Bulgaria 9
ES - Italia 8
HK - Hong Kong 8
AU - Australia 6
CH - Svizzera 6
AR - Argentina 5
BE - Belgio 5
RO - Romania 5
IE - Irlanda 4
IL - Israele 4
IR - Iran 4
RU - Federazione Russa 4
EE - Estonia 3
MX - Messico 3
TG - Togo 3
CO - Colombia 2
CZ - Repubblica Ceca 2
JO - Giordania 2
MO - Macao, regione amministrativa speciale della Cina 2
NL - Olanda 2
PE - Perù 2
TW - Taiwan 2
AL - Albania 1
GR - Grecia 1
GY - Guiana 1
JP - Giappone 1
MK - Macedonia 1
MY - Malesia 1
PH - Filippine 1
PL - Polonia 1
SA - Arabia Saudita 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 2.352
Città #
Fairfield 231
Rome 193
Chandler 114
Ashburn 102
Seattle 96
Woodbridge 94
Houston 76
Wilmington 65
Cambridge 63
Ann Arbor 60
San Paolo di Civitate 32
Princeton 31
Dearborn 30
Damanhur 29
Singapore 26
New York 25
Beijing 23
Helsinki 23
San Diego 23
Lawrence 21
Genoa 20
Millbury 20
Milan 17
Plano 17
Caserta 13
Boston 9
Sofia 9
Hong Kong 8
Seongnam 8
Boardman 7
Bremen 7
Civitavecchia 6
Fremont 6
Naples 6
Norwalk 6
Toronto 6
Federal 5
Grafing 5
Palermo 5
Andover 4
Birmingham 4
Dublin 4
Imperia 4
Kunming 4
Ottawa 4
Phoenix 4
Redwood City 4
Sacramento 4
Trois-rivières 4
Chicago 3
Geneva 3
Jacksonville 3
Leawood 3
Lomé 3
London 3
Los Angeles 3
Montreal 3
Nanjing 3
Paris 3
Perugia 3
Portland 3
Tallinn 3
Tel Aviv 3
Amman 2
Arezzo 2
Artena 2
Auburn Hills 2
Barcelona 2
Bergamo 2
Bhubaneswar 2
Bonn 2
Brasschaat 2
Brisbane 2
Bronte 2
Brooklyn 2
Brussels 2
Castegnero 2
Changsha 2
Conway 2
Corato 2
Des Moines 2
Duino-Aurisina 2
Faenza 2
Falls Church 2
Florence 2
Formello 2
Frosinone 2
Guwahati 2
Ibague 2
Jinan 2
Lappeenranta 2
Las Vegas 2
Leeds 2
Lima 2
Locate di Triulzi 2
Macao 2
Madrid 2
Manresa 2
New Delhi 2
Newton 2
Totale 1.693
Nome #
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway 149
The macrophage Galactose-type C-type Lectin (MGL) modulates regulatory T cell functions 135
Cancer immunotherapy in patients with brain metastases 115
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial 111
Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response 105
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab 104
Burned-out testicular cancer: really a different history? 101
MGL receptor and immunity: when the ligand can make the difference 92
P-158Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety 84
Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-Expressing Cells 83
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO) 82
Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer 74
Adjuvant chemotherapy in resected colon cancer: when, how and how long? 72
In vitro and in vivo anticancer action of saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells 66
Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study 66
Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer 65
E50Safety and toxicity in elderly patients in treatment for metastatic colon cancer 65
Merkel cell carcinoma of the retroperitoneum with no identifiable primary site 64
Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer 63
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients 63
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 61
Selective Internal Radiation Therapy (SIRT): a new emerging role for Breast Cancer Liver Metastases 59
RAS mutation conversion in bevacizumab-treated metastatic colorectal cancer patients: a liquid biopsy based study 59
Efficacy and tolerability of selective internal radiotherapy with Yttrium-90 as consolidation treatment after chemotherapy in metastatic colorectal cancer 55
HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse 52
null 49
Why the therapeutic impact of RAS mutation clearance in plasma ctDNA deserves to be further explored in metastatic colorectal cancer 48
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature 47
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 39
Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (Ncscl) treated with immune checkpoint inhibitors (icis): a prospective study 35
Prognostic value of the BIO-Ra Score in metastatic castration-resistant prostate cancer patients treated with Radium-223 after the European Medicines Agency restricted use: secondary investigations of the multicentric BIO-Ra study 34
null 33
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 31
The value of the multidisciplinary team in metastatic renal cell carcinoma: paving the way for precision medicine in toxicities management 27
Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study 26
Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program 21
About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients 17
Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis 17
Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of tribe and tribe-2 studies by GONO 12
Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab 11
First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review 9
Lenvatinib Versus Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis 7
A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases 5
Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor 5
null 5
null 3
null 3
Totale 2.529
Categoria #
all - tutte 7.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.693


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020487 37 14 12 16 45 70 69 73 54 43 29 25
2020/2021267 26 18 24 20 22 20 5 12 31 58 21 10
2021/2022386 20 11 21 12 47 17 23 21 33 32 98 51
2022/2023534 77 97 52 50 56 69 9 44 27 16 28 9
2023/2024521 29 49 24 52 53 86 34 60 3 56 37 38
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 2.529